Information Provided By: 
Fly News Breaks for April 26, 2018
EVHC
Apr 26, 2018 | 10:18 EDT
Raymond James analyst John Ransom recommends buying Envision Healthcare (EVHC) on weakness today related to noted short-seller Jim Chanos comments on CNBC that he thinks Mednax (MD) and Envision Healthcare "may be worth nothing." Ransom believes the thesis is "inaccurate" and believes Envision could be sold at 15x proforma 2019 EBITDA, which would equate to the low $50's, based on a similar sale price of the physician practice sold by Fresenius Medical (FMS). The analyst rates Envision Healthcare a Strong Buy with a $55 price target.
News For EVHC From the Last 2 Days
There are no results for your query EVHC
